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Background: Plenty of studies have demonstrated the prognostic value of various inflammation-based indexes in
cancer. This study was designed to investigate the prognostic value of the C-reactive protein/albumin (CRP/Alb)
ratio in esophageal squamous cell carcinoma.
Methods: A retrospective study of 423 cases with newly diagnosed esophageal squamous cell carcinoma was
conducted. We analyzed the association of the CRP/Alb ratio with clinicopathologic characteristics. The prognostic
value was explored by univariate and multivariate survival analysis. In addition, we compared the discriminatory
ability of the CRP/Alb ratio with other inflammation-based prognostic scores by evaluating the area under the
receiver operating characteristics curves (AUC), including the modified Glasgow Prognostic Score (mGPS), neutrophil
lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR).
Results: The optimal cut-off value was identified to be 0.095 for the CRP/Alb ratio. A higher level of the CRP/Alb
ratio was associated with larger tumor size (P < 0.001), poorer differentiation (P = 0.019), deeper tumor invasion (P = 0.003),
more lymph node metastasis (P = 0.015), more distant metastasis (P < 0.001) and later TNM stage (P < 0.001). The CRP/Alb
ratio was identified to be the only inflammation-based prognostic score with independent association with overall survival
by multivariate analysis (P = 0.031). The AUC value of the CRP/Alb ratio was higher compared with the NLR and PLR,
but not mGPS at 6, 12 and 24 months of follow-up. In addition, the CRP/Alb ratio could identify a group of patients
with mGPS score of 0 who had comparable overall survival with those with mGPS score of 1.
Conclusions: The CRP/Alb ratio is a novel but promising inflammation-based prognostic score in esophageal
squamous cell carcinoma. It is a valuable coadjutant for the mGPS to further identify patients’ survival differences.
Keywords: Esophageal squamous cell carcinoma, C-reactive protein, Albumin, The modified Glasgow Prognostic
Score, Inflammation-based prognostic score, SurvivalBackground
Esophageal cancer (EC) is one of the most common ma-
lignancies in the digestive system. The main pathological
subtypes include adenocarcinoma and squamous cell
carcinoma. Esophageal adenocarcinoma (EAC) is the
major subtype in some Western countries [1], while the
incidence of esophageal squamous cell carcinoma (ESCC)* Correspondence: xurh@sysucc.org.cn
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unless otherwise stated.is higher in some Asian countries, with China included
[2,3]. Although great progress has been made in the treat-
ment in recent decades, the prognosis of EC remains poor.
The American Joint Committee on Cancer (AJCC) and
the Union for International Cancer Control (UICC)
tumor-node-metastasis (TNM) staging system is the most
important prognostic indicator [4,5]. Recently increasing
researches focus on the identification of other promising
prognostic factors, and such research achievements, to
some degree, may not only contribute to the classification
and management of patients in clinical practice, but also
facilitate the progress of translational research.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stage, some other prognostic indicators have been discov-
ered by previous studies [6,7]. Nutritional conditions affect
patient outcomes with EC to a large extent, partially own-
ing to its anatomic location of upper digestive tract. Be-
sides, the levels of inflammation also play important roles
in patient status and tumor progression. Accordingly,
nutrition-based and/or inflammation-based prognostic in-
dicators, such as body mass index (BMI) [8], the modified
Glasgow Prognostic Score (mGPS) [9], the prognostic nu-
tritional index (PNI) [10], the neutrophil-lymphocyte ratio
(NLR) and the platelet-lymphocyte ratio (PLR) [9], have
emerged as prognostic factors in EC as well as various
other cancers [11-13].
The C-reactive protein albumin (CRP/Alb) ratio, a
novel inflammation-based prognostic score, has been
demonstrated to show outstanding prognostic value in
hepatocellular carcinoma compared with other estab-
lished inflammation-based prognostic scores [14]. In this
study, we aim to explore the prognostic performance of
the CRP/Alb ratio in Chinese patients with ESCC, and




All patients have provided written informed consent for
their information to be stored and used in the hospital
database. Study approval was obtained from independent
ethics committees at Sun Yat-sen University Cancer
Center. This study was conducted in accordance with
the ethical standards of the World Medical Association
Declaration of Helsinki.
Study population
We retrospectively reviewed the medical records of 649
cases with newly diagnosed esophageal malignancies
from October 1, 2006 to November 30, 2010 in Sun
Yat-sen University Cancer Center in Guangzhou, China.
Pathological diagnoses were carefully checked. We ex-
cluded patients without pathological diagnosis and pa-
tients diagnosed with other malignancies, such as EAC,
esophageal small cell carcinoma, esophageal carcinosar-
coma and so on. Only patients pathologically confirmed
with ESCC were enrolled in this study. One patient with
cervical cancer diagnosed within five years before the
diagnosis of ESCC was also excluded. Moreover, we also
excluded patients without pretreatment information of
nutrition and/or inflammation-based prognostic indica-
tors, patients lost to follow-up, as well as patients died
of non-cancer causes. Furthermore, to eliminate the in-
fluences of non-cancer diseases on inflammation-based
prognostic scores, we excluded patients with rheumatoid
diseases and acute infection. Finally, there were 423cases enrolled in our study. Clinicopathologic informa-
tion and pretreatment nutrition and inflammation-based
indexes were retrospectively collected.
Measurement of several tumor-related characteristics
The tumor stage was classified according to the AJCC/
UICC TNM staging system (the 7th edition). For the T
classification, most of the cases with stage I – III ESCC
were classified by post-operative pathological specimens.
There were thirteen cases classified as T4b after an ex-
ploratory thoracotomy and with unresectable locally in-
vasive tumors founded. The tumor size was defined as
the long diameter measured with post-operative patho-
logical specimens. The tumor locations were classified
into upper esophagus, middle esophagus and lower
esophagus. Because of the small numbers of tumors lo-
cated in cervical esophagus and gastroesophageal junction,
we categorized tumors located in cervical esophagus into
the upper esophagus group, and tumors located in gastro-
esophageal junction into the lower esophagus group in
this study.
Definitions of various nutrition and inflammation-based
prognostic scores
The nutrition and inflammation-based prognostic scores
in this study were defined and calculated as follows.
BMI: body mass index, calculated by weight (Kg)/height
(m) 2. mGPS: the Glasgow Prognostic Score, it was
the combination of CRP and albumin. Patients with
CRP < 10 mg/L were allocated a score of 0. Patients
with both CRP > 10 mg/L and albumin > 35 g/L were
allocated a score of 1. Patients with both CRP > 10 mg/L
and albumin < 35 g/L were allocated a score of 2. PNI: the
prognostic nutritional index, it was calculated by the
formula of 10 × albumin (g/dL) + 0.005× lymphocyte
count/uL. NLR: the neutrophil-lymphocyte ratio . PLR:
the platelet-lymphocyte ratio. CRP/Alb: the CRP (mg/L)-
albumin (g/L) ratio. All the indicators involved in the calcu-
lation of the nutrition and inflammation-based prognostic
scores were tested before surgery, chemotherapy and radio-
therapy treatment. Patients without pretreatment informa-
tion for these indicators or patients who had received
surgery, chemotherapy or radiotherapy in other hospitals
before they came to our center were both excluded from
this research. Therefore the impact of surgery, chemother-
apy and radiotherapy on these scores could be avoided.
Treatment and follow-up of patients
Patients of all TNM stages were enrolled in this study.
The treatment strategies were made according to the
National Comprehensive Cancer Network (NCCN) Clinical
Practice guidelines. Because patients involved in this study
were diagnosed from October 1, 2006 to November 30,
2010, the modality of therapy combination was diversiform.
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we categorized all the patients into two groups, including
curative treatment group and palliative treatment group.
The treatment purpose was determined according to both
the pretreatment examinations and the operation notes.
Follow-up schedules were established and applied refer-
ring to the NCCN Clinical Practice Guidelines. For pa-
tients who received curative treatment, they were followed
up at out-patient department every three months for the
first two years, then every six months for another three
years and every one year for the rest of time. Patients with
incurable disease continued to attend clinics or be hospi-
talized. For patients who didn’t follow the advice to come
back to our hospital, we had a special follow-up depart-
ment to make follow up telephone interviews.
Statistical analysis
Differences of baseline and clinicopathological parame-
ters between groups were evaluated by chi-square test,
Mann–Whitney U test or Kruskal-Wallis H test based
on the type of the data and comparison. Overall survival
(OS) was the time interval from the date of diagnosis to
death from ESCC or to the last date of follow-up. OS
curves were plotted with the Kaplan-Meier method, and
differences were compared with log-rank test. A Cox re-
gression was used for univariate and multivariate ana-
lysis. Hazard ratio (HR) and 95% confidence interval
(95% CI) were computed with the Cox proportional-
hazards model. Variables significantly prognostic in uni-
variate analysis were selected for multivariable analysis
using the forward stepwise method. The optimal cutoff
values for continuous prognostic indexes were deter-
mined with the method established by Jan Budczies et al.
at http://molpath.charite.de/cutoff/ [15]. To evaluate
the discriminatory ability of the inflammation-based prog-
nostic scores, receiver operating characteristics (ROC)
curves were generated, and the areas under the curve
(AUC) were measured and compared. The statistical ana-
lyses were performed with SPSS 17.0 (SPSS Inc., Chicago,
IL, USA). A two tailed P value <0.05 was considered sta-
tistically significant.
Results
There were 423 patients pathologically confirmed with
ESCC enrolled in this study. The median age was
58 years old, with an age range of 24 – 88 years old. The
majority of patients were males (n = 341, (80.6%)). The
numbers of patients from staged I to IV were 54
(12.8%), 168 (39.7%), 142 (33.6%), 59 (13.9%) respect-
ively. Thirty six (8.5%) patients were with tumors located
at upper esophagus, while there were 252 (59.6%) and
135 (31.9%) patients with tumors located at middle and
lower esophagus respectively. There were 363 (85.8%) pa-
tients received tumor resection. The numbers of patientsreceiving curative and palliative treatment were 358
(84.6%) and 65 (15.2%) respectively.
The value of the CRP/Alb ratio ranged from 0.0 – 7.9
with a median of 0.055. The optimal cut-off value of the
CRP/Alb ratio was determined to be 0.095 for the OS.
We analyzed the association of the CRP/Alb ratio
(≤0.095/> 0.095) with clinicopathologic characteristics of
patients (Table 1). There was no difference in the distri-
bution of age and sex between the two levels of the
CRP/Alb ratio. However, it was found that a higher
CRP/Alb ratio level (>0.095) was associated with more
lymph node metastasis (P = 0.015), deeper tumor invasion
(P = 0.003), more distant metastasis (P < 0.001) and more
advanced TNM stage (P < 0.001). It, besides, was also as-
sociated with larger size of esophageal tumors (P < 0.001)
and poorer tumor differentiation (P = 0.019). In addition,
there were more patients without resection of esophageal
tumors and received palliative treatment in the higher
CRP/Alb ratio level group (both P < 0.001).
The median follow-up time was 35.7 months, with a
range of 0.6 – 95.6 months. The median OS was
60.5 months for the whole cohort of patients. Com-
pared with a lower CRP/Alb ratio (≤0.095), a higher
CRP/Alb ratio (>0.095) was associated with significant
worse OS (P < 0.001, Figure 1). Other significant prog-
nostic indexes identified by univariate analysis included
age (≤54/> 54 yr), the TNM stage (I/II/III/IV), distant
metastasis (No/Yes), surgery (No/Yes), treatment pur-
pose (Curative treatment/Palliative treatment), BMI
(≤20.43/> 20.43), mGPS (0/1/2), PNI (≤49.05/> 49.05),
NLR (≤1.835/> 1.835), PLR (≤163.8/> 163.8), CRP (≤10/> 10),
white blood cell (WBC) (≤10/> 10), albumin (≤35/> 35).
The detailed results were shown in Table 2.
These variables were selected for multivariate analysis
using a forward stepwise method, and five indexes were
identified to be independent prognostic factors for OS.
They were age (HR 1.473, P = 0.015), the TNM stage
(P < 0.001), treatment purpose (HR 2.113, P = 0.025),
BMI (HR 0.663, P = 0.005) and the CRP/Alb ratio (HR
1.393, P = 0.031).
In order to further identify features of patients with
better value of the CRP/Alb ratio for prognostic applica-
tion in ESCC, we performed subgroup survival analysis.
The results were presented in Additional file 1: Table S1.
It was found that the CRP/Alb ratio remained to be a
significant prognostic factor in all subgroups except fe-
male patients, patients with upper esophageal tumors
and patients with curative treatment. However, in multi-
variate analysis, its prognostic value remained significant
in partial patients, including male patients, patients at
younger age (≤54), patients with moderately differenti-
ated tumors, patients with distant metastasis, patients
without esophageal tumor resection and patients with
palliative treatment.
Table 1 Correlation of the CRP/Alb ratio with the baseline
and clinicopathological characteristics of patients






Male 216 (78.3) 125 (85.0)
Female 60 (21.7) 22 (15.0)




I 41 (14.9) 13 (8.8)
II 131 (47.5) 37 (25.2)
III 81 (29.3) 61 (41.5)




N0 154 (59.7) 49 (47.6)
N1 58 (22.5) 23 (22.3)
N2 35 (13.6) 25 (24.3)




T1 32 (12.3) 10 (8.7)
T2 55 (21.1) 17 (14.8)
T3 171 (65.5) 75 (65.2)




M0 253 (91.7) 111 (75.5)
M1 23 (8.3) 36 (24.5)
Primary tumor
size (cm)
3.0 (0.5-11.0) 4.5 (1.0 -10.0) < 0.001*
Tumor location 0.129
Upper 29 (10.5) 7 (4.8)
Middle 160 (58.0) 92 (62.6)






93 (33.7) 66 (44.9)
Moderately
differentiated
173 (62.7) 78 (53.1)
Well
differentiated
10 (3.6) 3 (2.0)
Surgery < 0.001*
No 18 (6.5) 42 (28.6)
Table 1 Correlation of the CRP/Alb ratio with the baseline
and clinicopathological characteristics of patients
(Continued)






256 (92.8) 102 (69.4)
Palliative
treatment
20 (7.2) 45 (30.6)
*Significant differences between patients with the CRP/Alb ≤ 0.095 and
patients with the CRP/Alb > 0.095.
Abbreviation: TNM tumor-node-metastasis, AJCC American Joint Committee on
Cancer, CRP/Alb the C-reactive protein/Albumin ratio.
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ratio, a novel inflammation-based prognostic score with
that of other established inflammation-based prognostic
indexes, we generated ROC curves for the survival status
at 6 months, 1 year and 2 years of follow-up and statisti-
cally compared the differences of estimated AUC
(Table 3). It was found that at the follow-up of 1 year,
the AUC value of the CRP/Alb ratio was significantly
higher than that of the NLR and PLR. At the follow-up
of 2 years, the AUC value of CRP/Alb ratio remained to
be significantly higher than that of NLR. No significant
difference of AUC value was found between the CRP/
Alb ratio and mGPS. In addition, we found that along
with the extension of follow-up time, the TNM stage
remained to have higher discriminatory ability, while all
the inflammation-based scores showed decreased discrim-
inatory ability. The detailed information was demonstrated
in Table 3. The ROC curves of the inflammation-based
prognostic indexes were shown in Figure 2.Figure 1 The prognostic value of the CRP/Alb ratio by univariate
analysis. Compared with a lower CRP/Alb ratio (≤0.095), a higher
CRP/Alb ratio (>0.095) was associated with significant worse
OS (P < 0.001).
Table 2 Prognostic factors for overall survival identified by univariate and multivariate analyses
Characteristics Univariate analysis Multivariate analysis











Degree of differentiation 0.167
Poorly or not differentiated 159 (37.6)
Moderately differentiated 251 (59.3)
Poorly differentiated 13 (3.1)
TNM stage (AJCC, 7th) <0.001* <0.001*
I 54 (12.8) 1 Reference
II 168 (39.7) 1.913 0.973 – 3.760 0.060
III 142 (33.6) 4.231 2.178 – 8.220 <0.001*







Treatment purpose <0.001* 2.113 1.099 – 4.061 0.025*
Curative treatment 358 (84.6)
Palliative treatment 65 (15.2)
BMI (Kg/m2) <0.001* 0.663 0.496 – 0.885 0.005*
≤20.43 158 (37.4)
>20.43 257 (60.8)
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*Statistically significant prognostic factor identified by univariate/multivariate analysis.
Abbreviation: CI confidence interval, TNM tumor-node-metastasis, AJCC American Joint Committee on Cancer, BMI body mass index, CRP/Alb the C-reactive
protein/Albumin ratio, mGPS the modified Glasgow Prognostic Score, PNI the prognostic nutritional index, NLR the neutrophil lymphocyte ratio, PLR the platelet
lymphocyte ratio, CRP C-reactive protein, WBC white blood cell.
The cut-off values for age, BMI, CRP/Alb, PNI, NLR and PLR were determined by the method described in statistic analysis. CRP, WBC and Albumin were categorized
according to clinical normal reference range.
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(≤0.095/> 0.095) with other established nutrition and
inflammation-based prognostic indexes, including the
mGPS, PNI, NLR, PLR, CRP, WBC, albumin and BMI
(Table 4). It was found that the CRP/Alb ratio was associ-
ated with all these indexes (all P < 0.001, except for P =
0.001 for BMI). Interestingly, in terms of the mGPS score,
most of the patients (n = 345, 81.6%) were classified into
the group of score 0, and they were classified by the CRP/
Alb ratio (≤0.095/> 0.095) into two groups. However, no
patients with mGPS score of 1 and 2 had the CRP/Alb ra-
tio ≤ 0.095 (Table 4).
We further categorized patients into four groups ac-
cording to the mGPS score and CRP/Alb ratio level:
mGPS score of 0 &CRP/Alb ratio ≤ 0.095, mGPS score
of 0 & CRP/Alb ratio > 0.095, mGPS score of 1 and
mGPS score of 2. The Kaplan-Meier curves were shown
in Figure 3 (P <0.001). Patients with mGPS score of
0&CRP/Alb ≤ 0.095 had the best OS, while patients with
mGPS score of 0 & CRP/Alb > 0.095 and mGPS score of
1 had comparable moderate OS, and patients with mGPS
score of 2 had the worst OS.
Discussion
It has been recognized that inflammation is an import-
ant regulator in the genesis, progression and metastasis
of malignancies [16,17]. Inflammatory factors derive not
only from the systemic reaction to malignancies, but also
the secretion of tumor cells, including acute phase pro-
teins like CRP, [18,19] chemokines [20], cytokines like
interleukin 6 (IL-6) [21], transcription factor like NF-κB[22], circulating and infiltration immune cells [23] and
so on. The host factors and tumor factors interact with
each other, causing some systemic symptoms, such as
pyrexia and cachexia. Their interactions can also acceler-
ate tumor progression or result in tumor regression.
Thus the levels of inflammatory components have cer-
tain prognostic value in cancer, and this theory has been
demonstrated by extensive studies [12,14,24,25]. In
addition, malnutrition is correlated with poor perform-
ance status and worse survival [26]. To predict survival
of cancer patients expediently, previous researches have
established some nutrition and inflammation-based in-
dexes derived from routine tests, such as CRP, mGPS,
PNI, NLR, PLR, and Albumin.
The CRP/Alb ratio was primarily developed to identify
patients with serious illness on an acute medical ward by
Fairclough, E et al. [27]. Then another study assessed its
ability to predict 90-day mortality of septic patients [28].
More recently, Kinoshita, A et al. explored its prognostic
value in hepatocellular carcinoma. They found that it
had comparable performance with mGPS and better per-
formance than NLR [14]. Our study assessed the clinico-
pathologic relevance and prognostic value of the CRP/
Alb ratio in ESCC. We found that it had significant asso-
ciation with some important clinicopathologic characteris-
tics. In univariate analysis, all of the inflammation-based
prognostic indexes were found to be significant prognos-
tic. However, after adjusting for confounding factors, only
the CRP/Alb ratio remained to be a significant prognostic
factor. Besides, compared with the NLR and PLR, the
CRP/Alb ratio had better discriminatory ability. What’s
Table 3 Comparisons of the discriminatory ability of prognostic scores by comparing the AUC
Indexes AUC 95% CI P value Significance of comparison §P’ value
6 months of follow-up
TNM stage (AJCC, 7th) 0.752 0.658 – 0.847 <0.001* 0.53
CRP/Alb (continuous) 0.706 0.597 – 0.815 <0.001* -
CRP/Alb (categorical) 0.702 0.604 – 0.800 <0.001* -
mGPS 0.665 0.550 – 0.781 0.003* 0.61
NLR (continuous) 0.649 0.553 – 0.745 0.007* 0.44
NLR (categorical) 0.584 0.484 – 0.683 0.132 0.09
PLR (continuous) 0.650 0.557 – 0.743 0.007* 0.45
PLR (categorical) 0.563 0.450 – 0.677 0.255 0.07
1 year of follow-up -
TNM stage (AJCC, 7th) 0.706 0.642 – 0.771 <0.001* 0.87
CRP/Alb (continuous) 0.698 0.631 – 0.765 <0.001* -
CRP/Alb (categorical) 0.670 0.600 – 0.739 <0.001* -
mGPS 0.626 0.550 – 0.701 0.001* 0.16
NLR (continuous) 0.576 0.506 – 0.645 0.040* 0.01*
NLR (categorical) 0.552 0.482 – 0.621 0.162 0.02*
PLR (continuous) 0.584 0.509 – 0.659 0.022* 0.03*
PLR (categorical) 0.574 0.499 – 0.648 0.046* 0.06
2 years of follow-up
TNM stage (AJCC, 7th) 0.731 0.680 – 0.783 <0.001* 0.02*
CRP/Alb (continuous) 0.638 0.579 – 0.697 <0.001* -
CRP/Alb (categorical) 0.619 0.560 – 0.679 <0.001* -
mGPS 0.574 0.513 – 0.636 0.015* 0.14
NLR (continuous) 0.555 0.496 – 0.614 0.074 0.05*
NLR (categorical) 0.550 0.491 – 0.609 0.102 0.10
PLR (continuous) 0.566 0.506 – 0.626 0.031* 0.09
PLR (categorical) 0.556 0.495 – 0.617 0.067 0.14
*Significant P value of ROC curves analysis.
Abbreviation: ROC receiver operating characteristics, AUC area under the curves, TNM tumor-node-metastasis, AJCC American Joint Committee on Cancer, CRP/Alb
the C-reactive protein/Albumin ratio, mGPS the modified Glasgow Prognostic Score, NLR the neutrophil lymphocyte ratio, PLR the platelet lymphocyte ratio.
§ Comparisons of AUC values were made between the CRP/Alb ratio and other inflammation-based prognostic factors using z test method, a two tailed P value <0.05
was considered statistically significant. Significant differences were marked with “*”. Continuous indexes were compared with the CRP/Alb ratio as a continuous variable,
while categorical indexes were compared with the CRP/Alb ratio as a categorical variable.
Figure 2 The ROC curves of inflammation-based prognostic indexes at 6, 12 and 24 months of follow-up. This figure showed the ROC curves of the CRP/
Alb ratio (continuous), NLR (continuous), PLR (continuous) and mGPS (categorical) for the survival status at 6 months, 1 year and 2 years of follow-up.
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Table 4 Correlation of the CRP/Alb ratio with other
nutrition and/or inflammation-based prognostic scores
Characteristic No. of Patients (%) P value
CRP/Alb ≤ 0.095 CRP/Alb > 0.095
mGPS <0.001*
0 276 (100) 69 (46.9)
1 0 70 (47.6)
2 0 8 (5.4)
PNI 53.8 (41.9 - 70.6) 50.4 (33.5 - 59.6) <0.001*
NLR 1.9 (0.5 - 28.0) 3.2 (1.2 - 27.7) <0.001*
PLR 111.5 (0.8 – 990.0) 147.1 (55.2 – 830.0) <0.001*
CRP (mg/L) 1.2 (0.1 – 4.5) 10.6 (3.9 – 233.0) <0.001*
WBC (×10^9/L) 6.7 (1.7 – 15.7) 8.4 (3.8 – 23.9) <0.001*
Albumin (g/L) 43.8 (36.1 – 54.6) 41.7 (29.5 – 48.6) <0.001*
BMI (Kg/ m2) 21.5 (14.9 – 30.1) 20.6 (13.4 – 32.2) 0.001*
*Statistically significant differences of distribution between patients with the
CRP/Alb ratio ≤ 0.095 and patients with the CRP/Alb ratio > 0.095.
Abbreviation: CRP/Alb the C-reactive protein/Albumin ratio, mGPS the modified
Glasgow Prognostic Score, PNI the prognostic nutritional index, NLR the
neutrophil lymphocyte ratio, PLR the platelet lymphocyte ratio, CRP C-reactive
protein, WBC white blood cell, BMI body mass index.
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all these inflammation-based prognostic indexes, suggest-
ing that it might absorb the prognostic value of all those
indexes and had a combined predictive effect. In general,
these results indicated that the CRP/Alb ratio was a novel
and promising inflammation-based prognostic score in
ESCC.Figure 3 The prognostic value by Kaplan-Meier curves of the combination
groups according to the mGPS score and CRP/Alb level: mGPS score of 0 &
and mGPS score of 2. Patients with a mGPS score of 0&CRP/Alb≤ 0.095 ha
CRP/Alb > 0.095 and a mGPS score of 1 had comparable moderate overall
overall survival.The the CRP/Alb ratio and mGPS were both calcu-
lated with the same indexes, CRP and albumin. Since
the mGPS was one of the best acknowledged and dem-
onstrated inflammation-based prognostic scores in var-
ieties of cancer scenarios [11], it drew special attention
to compare the prognostic value of the two prognostic
scores. Although the multivariate analysis showed that
the CRP/Alb ratio was an independent prognostic factor
for OS while the mGPS was a confounding factor, the
comparison of AUC value identified no differences in
the discriminatory ability between the two prognostic
scores. What further caught our attention was that when
classified by the mGPS, there were 81.6% of patients
classified in the group of a score of 0, which meant that
the mGPS couldn’t distinguish the survival differences of
most of the patients in this study. This was in consistent
with some previous researches in EC [9,29]. We sug-
gested that the combination of the mGPS and CRP/Alb
ratio would better distinguish the survival differences of
cancer patients. Thus we categorized patients into four
groups and explored their survival differences: mGPS
score of 0 &CRP/Alb ≤ 0.095, mGPS score of 0 & CRP/
Alb > 0.095, mGPS score of 1 and mGPS score of 2. It
could be found that ARP/Alb identified a group of pa-
tients with mGPS score of 0 to have comparable survival
with mGPS score of 1. As a continuous score, the CRP/
Alb might have the ability to identify tiny differences
among patients classified into the same group by the
mGPS score. Therefore the CRP/Alb would be a signifi-
cant coadjutant for the mGPS to predict survival.of the CRP/Alb ratio and mGPS. All patients were classified into four
CRP/Alb≤ 0.095, mGPS score of 0 & CRP/Alb > 0.095, mGPS score of 1
d the best overall survival, while patients with a mGPS score of 0 &
survival, and patients with a mGPS score of 2 had the worst
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with lower BMI level and albumin level (Table 4). As a
matter of fact, the association between inflammation
and nutrition had been comfirmed by plenty of re-
searches, and systemic inflammatory response was found
to be related to poor performance status, nutritional de-
cline and subsequent poor outcome in cancer patients
[30-33]. Several studies proved that supplement of some
trophic factors, for example, ω-3 polyunsaturated fatty
acids, could improve plasma fatty acid profile, CRP/Alb
status, and immune function and prevent weight loss
during treatment in cancer patients [34,35]. Since CRP/
Alb ratio was related with not only other inflammation-
based indexes, but also nutrition-based indexes, as well
as both short and long-term outcomes of patients, it
would probably be an appropriate index to evaluate and
predict the effectiveness of nutrition improvement treat-
ment of cancer patients in clinical practice.
Our study indicated that the CRP/Alb level was associ-
ated with aggressive behavior. The mechanism of how
inflammation regulates tumor behavior and host status
was complicated. The production of CRP was independ-
ently mediated by IL-6 level [36]. This way of regulation
was partially responsible for poor response to chemora-
diotherapy in patients with EC [37]. IL-6 also stimulated
recruitment of myeloid-derived suppressor cells, and in-
duced invasive tumor in ESCC [38]. STAT3 and NF-κB
could be activated by IL-6 to prevent apoptosis and pro-
mote proliferation of malignant tumor cells [16]. In
addition, the phenotype of infiltrating immune cells in
the tumor microenvironment was mediated by cyto-
kines, chemokines and other inflammatory mediators
[16]. And immune cell infiltration was a prognostic
marker in ESCC [39]. Mesenchymal stem cells were also
found to have some interactions with inflammation in
tumor microenvironment [40]. Above were the examples
of mechanism of inflammation-related tumor invasive
characteristics. Cachexia was a common and devastating
symptom in malignancies. It was induced by metabolic
dysfunction resulted from complex crosstalk of inflam-
matory cytokines. Other symptoms such as fever, weight
loss and fatigue were all associated with higher concen-
trations of certain inflammatory factors [41]. However,
there was still some room for more and deepened re-
searches, and therapeutic application directing at malig-
nant inflammation was promising.
The main limitation of our study was that it was con-
ducted retrospectively in a single center, and the prog-
nostic value of the CRP/Alb ratio was not verified in a
validation cohort. Besides, there was large heterogeneity
in the patient treatment, thus it was hard to analyze the
impact of the CRP/Alb ratio on patients outcome in dif-
ferent treatment patterns. In addition, compared with
the mGPS, the continuity of the CRP/Alb ratio requiredan optimal cut-off value in clinical practice. However, it
might be feasible to find an optimal cut-off value for
each tumor stage. In conclusion, our study demonstrated
the CRP/Alb ratio to be a promising inflammation-based
prognostic score. It was significantly associated with more
invasive clinicopathologic characteristics and worse pa-
tient outcomes in ESCC. It was superior to some estab-
lished inflammation-based prognostic indexes, including
the NLR and PLR. Last but not least, it was a valuable
coadjutant for the mGPS to predict OS of patients with
ESCC. The prognostic value of the CRP/Alb ratio should
be further evaluated in larger prospective studies and
other malignancies.
Conclusions
Our study demonstrated that the CRP/Alb ratio was asso-
ciated with some important clinicopathological character-
istics in ESCC, including tumor size (P < 0.001), tumor
differentiation (P = 0.019), T stage (P = 0.003), N stage
(P = 0.015), M stage (P < 0.001) and TNM stage (P < 0.001).
In addition, a higher CRP/Alb ratio was associated with
worse OS (P = 0.031 by multivariate analysis). Compared
with the NLR and PLR, the CRP/Alb ratio showed a super-
ior discriminatory ability. Although no statistical difference
of discriminatory ability was found between the CRP/Alb
ratio and the mGPS, the CRP/Alb ratio could identify a
group of patients with mGPS score of 0, who had com-
parable overall survival with those with mGPS score of
1 (P < 0.001). In conclusion, our study demonstrated the
CRP/Alb ratio to be a novel and promising prognostic
inflammation-based factor in ESCC.
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